BDTX

Black Diamond Therapeutics, Inc. [BDTX] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

BDTX Stock Summary

Top 10 Correlated ETFs

BDTX


Top 10 Correlated Stocks

BDTX


In the News

10:55 28 Mar 2024 BDTX

How Much Upside is Left in Black Diamond Therapeutics (BDTX)? Wall Street Analysts Think 95.93%

The mean of analysts' price targets for Black Diamond Therapeutics (BDTX) points to a 95.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

05:21 28 Mar 2024 BDTX

Black Diamond Therapeutics: Emerging Data In EGFR-Mutant NSCLC And GBM

Black Diamond Therapeutics is a precision oncology company targeting genetically defined cancers with its Masterkey approach. Besides NSCLC, BDTX also produced positive early data in recurrent GBM, a notoriously hard-to-treat disease. The company plans to initiate enrollments for expansion cohorts and seek FDA feedback for additional studies on various doses of BDTX-1535.

08:00 28 Mar 2024 BDTX

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass. and NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with genetically defined cancers, today announced that its President and Chief Executive Officer, Mark A. Velleca, M.D., Ph.D., will participate in fireside chats during two upcoming investor conferences:

12:14 28 Mar 2024 BDTX

Black Diamond Therapeutics to Present Preclinical and Clinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

CAMBRIDGE, Mass. and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company developing therapies that target families of oncogenic mutations in patients with genetically defined cancers, today announced forthcoming presentations during the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, October 11-15, 2023. The three poster presentations include initial dose escalation data from the Company's Phase 1 clinical trial of BDTX-1535 in non-small cell lung cancer (NSCLC), the study design of this ongoing Phase 1 clinical trial, and preclinical data for BDTX-4933.

08:00 28 Mar 2024 BDTX

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass. and NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with genetically defined cancers, today announced that company management will participate in three upcoming investor conferences:

05:48 28 Mar 2024 BDTX

Why Shares of Black Diamond Therapeutics Skyrocketed This Week

Lung cancer is the deadliest form of cancer in the U.S. Black Diamond Therapeutics' NSCLC therapy is in early trials. The pharmaceutical company used the positive news to raise funds through a stock sale.

11:56 28 Mar 2024 BDTX

Black Diamond Therapeutics stock rockets after positive trial data shows anti-tumor activity

Black Diamond Therapeutics Inc shares doubled after it saw positive initial dose escalation data from a study demonstrating the anti-tumor activity of BDTX-1535 in non-small cell lung (NSCL) cancer patients. The new data from the dose escalation portion of the Phase 1 study demonstrated clinical proof of activity of BDTX-1535 in NSCL cancer patients with both acquired resistance and intrinsic driver epidermal growth factor receptor (EGFR) mutations.

11:00 28 Mar 2024 BDTX

Why Is Black Diamond Therapeutics (BDTX) Stock Up 82%?

Black Diamond Therapeutics (NASDAQ: BDTX ) stock is seeing massive gains on Tuesday after releasing data from the dose escalation portion of the Phase 1 clinical study. That clinical trial covers the use of BDTX-1535 as a treatment for non-small cell lung cancer (NSCLC) and glioblastoma multiforme (GBM).

08:00 28 Mar 2024 BDTX

Black Diamond Therapeutics to Present at the Jefferies Healthcare Conference

CAMBRIDGE, Mass. and NEW YORK, June 02, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology medicine company developing MasterKey therapies designed to overcome limitations of existing therapies by targeting families of oncogenic driver mutations in patients with genetically defined cancers, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an overview of the Company's MasterKey programs, including BDTX-1535 and BDTX-4933, at the Jefferies Healthcare Conference on Friday, June 9, 2023, at 12:45 p.m. ET in New York, NY.

08:00 28 Mar 2024 BDTX

Black Diamond Therapeutics to Present at the Cowen 43rd Annual Health Care Conference

CAMBRIDGE, Mass. and NEW YORK, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology medicine company developing novel MasterKey therapies targeting families of oncogenic driver mutations in patients with genetically defined cancers, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update on the Company's progress at the Cowen 43rd Annual Health Care Conference on Monday, March 6, 2023, at 12:50 p.m. ET in Boston, MA.

BDTX Financial details

Company Rating
Neutral
Market Cap
296.86M
Income
-81.76M
Revenue
0
Book val./share
2.26
Cash/share
2.54
Dividend
-
Dividend %
-
Employees
54
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
-1.95
Forward P/E
-2.65
PEG
1.06
P/S
-
P/B
1.15
P/C
1.93
P/FCF
-2.11
Quick Ratio
9.57
Current Ratio
9.76
Debt / Equity
0.22
LT Debt / Equity
0.19
-
-
EPS (TTM)
-1.9
EPS next Y
-1.85
EPS next Q
-0.43
EPS this Y
-19.31%
EPS next Y
-2.42%
EPS next 5Y
-36.32%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-15.56%
-
-
-
-
SMA20
2.66%
SMA50
74.56%
SMA100
165.08%
Inst Own
80.79%
Inst Trans
0.73%
ROA
-46%
ROE
67%
ROC
-0.56%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
51.72M
Shs Float
38.11M
-
-
-
-
Target Price
-
52W Range
1.43-6.85
52W High
-18.33%
52W Low
+390%
RSI
54.02
Rel Volume
0.67
Avg Volume
603.85K
Volume
404.26K
Perf Week
4.26%
Perf Month
18.36%
Perf Quarter
92.16%
Perf Half Y
54.57%
-
-
-
-
Beta
2.653
-
-
Volatility
0.37%, 0.43%
Prev Close
-3.73%
Price
4.9
Change
-6.84%

BDTX Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-1.26-1.99-3.4-2.33-1.88
Operating cash flow per share
-0.76-1.58-2.77-2.35-1.52
Free cash flow per share
-0.76-1.59-2.84-2.35-1.52
Cash per share
4.749.575.83.392.99
Book value per share
-1.56-3.59-6.74-9.252.66
Tangible book value per share
-1.569.35-6.743.192.66
Share holders equity per share
-1.56-3.59-6.74-9.252.66
Interest debt per share
6.150.270.790.670.58
Market cap
1.29B1.05B192.89M65.21M123.51M
Enterprise value
1.33B1.03B155.55M59.04M92.59M
P/E ratio
-31.32-16.11-1.57-0.77-1.5
Price to sales ratio
00000
POCF ratio
-52.22-20.23-1.93-0.77-1.85
PFCF ratio
-52.18-20.17-1.88-0.76-1.85
P/B Ratio
-25.28-8.92-0.79-0.191.06
PTB ratio
-25.28-8.92-0.79-0.191.06
EV to sales
00000
Enterprise value over EBITDA
-58.17-15.3-1.24-0.62-1.08
EV to operating cash flow
-54.08-19.73-1.55-0.69-1.39
EV to free cash flow
-54.03-19.68-1.51-0.69-1.39
Earnings yield
-0.03-0.06-0.64-1.3-0.67
Free cash flow yield
-0.02-0.05-0.53-1.31-0.54
Debt to equity
-3.94-0.07-0.12-0.080.22
Debt to assets
1.270.030.110.180.16
Net debt to EBITDA
-20.380.30.060.36
Current ratio
31.822.488.878.376.82
Interest coverage
0-69.57K023.750
Income quality
0.70.780.80.930.81
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
000.0300
Capex to revenue
00000
Capex to depreciation
-0.45-2.73-13.22-0.38-0.08
Stock based compensation to revenue
00000
Graham number
6.6612.6822.7222.0310.59
ROIC
-0.070.670.670.32-0.53
Return on tangible assets
-0.26-0.2-0.5-0.54-0.52
Graham Net
-1.678.91-7.782.272.04
Working capital
149.8M305.34M186.14M112.45M114.39M
Tangible asset value
-50.97M307.76M-243.82M115.7M116.74M
Net current asset value
-54.6M297.64M-281.72M87.15M92.2M
Invested capital
-3.94-0.07-0.12-0.080.22
Average receivables
00000
Average payables
1.19M2.25M3.32M2.99M2.1M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
15.25K1.54K676.16211.581.94K
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
0.020.240.541.730.19
Inventory turnover
00000
ROE
0.810.550.510.25-0.71
Capex per share
00-0.07-0.010

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-0.47-0.55-0.52-0.45-0.38
Operating cash flow per share
-0.6-0.55-0.39-0.36-0.27
Free cash flow per share
-0.6-0.55-0.39-0.36-0.27
Cash per share
3.372.832.452.832.54
Book value per share
-9.21-9.752.252.642.26
Tangible book value per share
3.182.692.252.642.26
Share holders equity per share
-9.21-9.752.252.642.26
Interest debt per share
0.740.730.730.510.49
Market cap
65.5M68.95M184.41M146.21M145.1M
Enterprise value
59.33M57.27M169.28M114.27M114.18M
P/E ratio
-0.96-0.85-2.41-1.59-1.87
Price to sales ratio
00000
POCF ratio
-2.99-3.44-12.83-7.96-10.4
PFCF ratio
-3.01-3.44-12.83-7.95-10.4
P/B Ratio
-0.2-0.192.241.091.24
PTB ratio
-0.2-0.192.241.091.24
EV to sales
00000
Enterprise value over EBITDA
-2.46-2.66-8.5-4.76-5.5
EV to operating cash flow
-2.7-2.86-11.78-6.22-8.18
EV to free cash flow
-2.73-2.86-11.78-6.21-8.18
Earnings yield
-0.26-0.29-0.1-0.16-0.13
Free cash flow yield
-0.33-0.29-0.08-0.13-0.1
Debt to equity
-0.08-0.080.330.190.22
Debt to assets
0.180.20.220.150.16
Net debt to EBITDA
0.260.540.761.331.49
Current ratio
8.378.46.699.766.82
Interest coverage
16.1431.43000
Income quality
1.040.960.750.80.72
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
-0.010000
Capex to revenue
00000
Capex to depreciation
1.5900-0.290
Stock based compensation to revenue
00000
Graham number
9.8511.025.155.184.37
ROIC
0.070.07-0.14-0.13-0.13
Return on tangible assets
-0.11-0.15-0.16-0.13-0.12
Graham Net
2.261.811.422.081.73
Working capital
112.45M95.13M79.09M131.98M114.39M
Tangible asset value
115.7M98.19M82.2M134.32M116.74M
Net current asset value
87.15M70.59M55.31M108.98M92.2M
Invested capital
-0.08-0.080.330.190.22
Average receivables
00000
Average payables
3.82M2.46M2.89M1.72M1.51M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
209.33337.61303.3675.892.43K
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
0.430.270.31.190.04
Inventory turnover
00000
ROE
0.050.06-0.23-0.17-0.17
Capex per share
0.010000

BDTX Frequently Asked Questions

What is Black Diamond Therapeutics, Inc. stock symbol ?

Black Diamond Therapeutics, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol BDTX

What is Black Diamond Therapeutics, Inc. stock quote today ?

Black Diamond Therapeutics, Inc. stock price is $4.9 today.

Is Black Diamond Therapeutics, Inc. stock public?

Yes, Black Diamond Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap